Systemic Bio Named a Top 10 Finalist for the SLAS 2025 Innovation Award
Systemic Bio, a 3D Systems (NYSE: DDD) company, has been selected as a Top 10 Finalist for the SLAS 2025 Innovation Award. The company's proprietary h-VIOS™ platform, which accelerates drug discovery using bioprinted tissues, earned this recognition at the SLAS International Conference and Exhibition.
Operating from a Houston-based ISO 7 clean room facility under a Quality Management System, Systemic Bio can produce thousands of tissue models that mimic human organ systems with high precision. The platform represents a significant advancement in preclinical testing, supporting collaborations with leading pharmaceutical companies.
CEO Taci Pereira emphasized the recognition's significance in highlighting their platform's transformative potential in pharmaceutical innovation. Systemic Bio will present "h-VIOS: A human-relevant drug discovery and development platform using bioprinted human tissues" at the SLAS Conference in San Diego on January 27, 2025. The winner announcement is scheduled for January 29, 2025.
Systemic Bio, un'azienda di 3D Systems (NYSE: DDD), è stata selezionata come Top 10 Finalist per il Premio Innovazione SLAS 2025. La piattaforma proprietaria h-VIOS™ dell'azienda, che accelera la scoperta di farmaci utilizzando tessuti bioprintati, ha ricevuto questo riconoscimento durante la Conferenza e Esposizione Internazionale SLAS.
Operando da un impianto ISO 7 a Houston, sotto un Sistema di Gestione della Qualità, Systemic Bio è in grado di produrre migliaia di modelli di tessuto che imitano con alta precisione i sistemi di organi umani. La piattaforma rappresenta un notevole progresso nei test preclinici, sostenendo collaborazioni con le principali aziende farmaceutiche.
Il CEO Taci Pereira ha sottolineato l'importanza di questo riconoscimento nel mettere in evidenza il potenziale trasformativo della loro piattaforma nell'innovazione farmaceutica. Systemic Bio presenterà "h-VIOS: una piattaforma di scoperta e sviluppo di farmaci rilevante per l'uomo utilizzando tessuti umani bioprintati" alla Conferenza SLAS di San Diego il 27 gennaio 2025. L'annuncio del vincitore è previsto per il 29 gennaio 2025.
Systemic Bio, una empresa de 3D Systems (NYSE: DDD), ha sido seleccionada como Finalista de Top 10 para el Premio Innovación SLAS 2025. La plataforma propietaria h-VIOS™ de la compañía, que acelera el descubrimiento de fármacos utilizando tejidos bioprintados, recibió este reconocimiento en la Conferencia y Exposición Internacional SLAS.
Operando desde una instalación con sala limpia ISO 7 en Houston bajo un Sistema de Gestión de Calidad, Systemic Bio puede producir miles de modelos de tejido que imitan con alta precisión los sistemas de órganos humanos. La plataforma representa un avance significativo en las pruebas preclínicas, apoyando colaboraciones con las principales compañías farmacéuticas.
La CEO Taci Pereira enfatizó la importancia de este reconocimiento para resaltar el potencial transformador de su plataforma en la innovación farmacéutica. Systemic Bio presentará "h-VIOS: una plataforma relevante para la descubrimiento y desarrollo de fármacos utilizando tejidos humanos bioprintados" en la Conferencia SLAS en San Diego el 27 de enero de 2025. El anuncio del ganador está programado para el 29 de enero de 2025.
Systemic Bio는 3D Systems(NYSE: DDD)의 자회사로 SLAS 2025 혁신상을 위한 상위 10개 최종 후보로 선정되었습니다. 생체 프린팅된 조직을 사용하여 약물 발견을 가속화하는 회사의 고유한 h-VIOS™ 플랫폼은 SLAS 국제 컨퍼런스 및 전시회에서 이 인정을 받았습니다.
휴스턴에 위치한 ISO 7 클린룸 시설에서 품질 관리 시스템 하에 운영되는 Systemic Bio는 인간 장기 시스템을 정밀하게 모방한 수천 개의 조직 모델을 생산할 수 있습니다. 이 플랫폼은 전임상 시험의 중요한 발전을 나타내며, 주요 제약 회사들과의 협업을 지원합니다.
CEO Taci Pereira는 이 인식이 제약 혁신에서 그들의 플랫폼의 변혁적인 잠재력을 강조하는 중요성을 강조했습니다. Systemic Bio는 2025년 1월 27일 샌디에이고에서 열리는 SLAS 컨퍼런스에서 "h-VIOS: 생체 프린팅된 인간 조직을 사용하는 인간 관련 약물 발견 및 개발 플랫폼"을 발표할 예정입니다. 수상자는 2025년 1월 29일 발표될 예정입니다.
Systemic Bio, une entreprise de 3D Systems (NYSE: DDD), a été sélectionnée comme Top 10 Finaliste pour le Prix d'Innovation SLAS 2025. La plateforme propriétaire h-VIOS™ de l'entreprise, qui accélère la découverte de médicaments en utilisant des tissus bioprintés, a reçu cette reconnaissance lors de la Conférence et Exposition Internationale SLAS.
Fonctionnant depuis une installation à Houston certifiée ISO 7 sous un Système de Gestion de la Qualité, Systemic Bio peut produire des milliers de modèles de tissus qui imitent avec précision les systèmes organiques humains. La plateforme représente une avancée significative dans les tests précliniques, soutenant des collaborations avec des entreprises pharmaceutiques de premier plan.
La CEO Taci Pereira a souligné l'importance de cette reconnaissance pour mettre en avant le potentiel transformateur de leur plateforme dans l'innovation pharmaceutique. Systemic Bio présentera "h-VIOS : une plateforme pertinente pour la découverte et le développement de médicaments utilisant des tissus humains bioprintés" lors de la Conférence SLAS à San Diego le 27 janvier 2025. L'annonce du vainqueur est prévue pour le 29 janvier 2025.
Systemic Bio, ein Unternehmen von 3D Systems (NYSE: DDD), wurde als Top 10 Finalist für den SLAS 2025 Innovationspreis ausgewählt. Die proprietäre h-VIOS™ Plattform des Unternehmens, die die Medikamentenentdeckung durch bioprintete Gewebe beschleunigt, erhielt diese Anerkennung auf der SLAS Internationalen Konferenz und Ausstellung.
Systemic Bio produziert in einer auf ISO 7 zertifizierten Reinraumeinrichtung in Houston unter einem Qualitätsmanagementsystem tausende von Gewebemodellen, die menschliche Organsysteme präzise nachahmen. Die Plattform stellt einen bedeutenden Fortschritt in der präklinischen Forschung dar und unterstützt die Zusammenarbeit mit führenden Pharmaunternehmen.
CEO Taci Pereira hob die Bedeutung dieser Auszeichnung hervor, um das transformative Potenzial ihrer Plattform in der pharmazeutischen Innovation zu betonen. Systemic Bio wird am 27. Januar 2025 auf der SLAS-Konferenz in San Diego "h-VIOS: Eine relevante Plattform für die Medikamentenentdeckung und -entwicklung mit bioprintetem menschlichem Gewebe" vorstellen. Die Bekanntgabe des Gewinners ist für den 29. Januar 2025 geplant.
- None.
- None.
HOUSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Systemic Bio™, a 3D Systems company (NYSE: DDD), is honored to announce its selection as a Top 10 Finalist for the prestigious SLAS 2025 Innovation Award. This recognition underscores the groundbreaking potential of Systemic Bio’s proprietary h-VIOS™ platform geared at accelerating drug discovery and development using human-relevant data from bioprinted tissues.
The SLAS Innovation Award, presented annually at the SLAS International Conference and Exhibition, celebrates the most innovative technologies poised to impact laboratory science and automation. Systemic Bio was recognized for its cutting-edge platform, which leverages advanced bioprinting technologies to create complex vascularized tissue models.
“We are thrilled to be recognized by SLAS as a Top 10 Finalist for their esteemed Innovation Award,” said Taci Pereira, CEO of Systemic Bio. “This acknowledgment reflects the hard work and ingenuity of our team and highlights the transformative power of our platform in driving innovation within the pharmaceutical industry. By providing more accurate and predictive tools, we aim to accelerate the development of safer and more effective therapies for patients worldwide.”
Systemic Bio’s platform represents a paradigm shift in drug development, addressing longstanding challenges in preclinical testing by providing bioprinted tissue models that mimic human organ systems with unprecedented precision and throughput. Operating from a state-of-the-art facility in Houston, Systemic Bio has the capacity to produce thousands of tissue models from its ISO 7 clean room under a Quality Management System (QMS). These advanced models power the company’s innovative development efforts and drive its collaborations with world-leading pharmaceutical companies.
Systemic Bio will deliver a presentation, “h-VIOS: A human-relevant drug discovery and development platform using bioprinted human tissues,” at the SLAS Conference in San Diego on Monday, January 27, 2025, from 4:00 - 4:30 p.m. Pacific Standard Time. The winner will be announced on Wednesday, January 29, 2025 at 4:15 p.m., directly following the closing keynote presentation.
For more information about Systemic Bio and its pioneering work, please visit www.systemic.bio.
Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Systemic Bio or 3D Systems, as applicable, to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "believes," "belief," "expects," "may," "will," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the beliefs and expectations of Systemic Bio or 3D Systems as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the applicable company. The factors described under the headings "Forward-Looking Statements" and "Risk Factors" in 3D Systems’ periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. Neither Systemic Bio nor 3D Systems undertakes any obligation to update or revise any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law.
About Systemic Bio
Systemic Bio is a biotech company focused on accelerating drug discovery and development with human-relevant data from its proprietary platform of bioprinted vascularized organ models. Founded in 2022 as a wholly-owned company of 3D Systems, Systemic Bio leverages 3D Systems’ breakthrough, production-level bioprinting technology to create extremely precise healthy and diseased tissues using biomaterials and human cells. These proprietary organs-on-chips can be manufactured reproducibly in large quantities, and then perfused with drugs to study the effects on healthy or diseased tissue at the earliest stages of pharmaceutical drug development. These systems are multimodal and can be used to generate large datasets leveraged with machine learning to generate human-relevant therapeutic insights. More information on the company is available at www.systemic.bio.
About 3D Systems
More than 35 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading additive manufacturing solutions partner, we bring innovation, performance, and reliability to every interaction - empowering our customers to create products and business models never before possible. Thanks to our unique offering of hardware, software, materials, and services, each application-specific solution is powered by the expertise of our application engineers who collaborate with customers to transform how they deliver their products and services. 3D Systems’ solutions address a variety of advanced applications in healthcare and industrial markets such as medical and dental, aerospace & defense, automotive, and durable goods. More information on the company is available at www.3dsystems.com.
| Investor Contact: | investor.relations@3dsystems.com |
| Media Contact: | press@systemic.bio |
FAQ
What is the significance of Systemic Bio's Top 10 Finalist position for DDD stock?
How does Systemic Bio's h-VIOS platform impact drug development processes?
When will Systemic Bio present at the SLAS 2025 Conference?
What production capacity does Systemic Bio's Houston facility offer?
How does Systemic Bio's technology differentiate from traditional drug testing methods?
